November 7, 2025

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study | Blood Cancer Journal – Nature

November 6, 2025

Darzalex Faspro® Now FDA-Approved for Patients with High-Risk Smoldering Myeloma

Updated 11/6/2025 The FDA has approved Darzalex Faspro® (a version of daratumumab given as an injection under the skin) for use in certain patients with high-risk smoldering multiple myeloma (SMM). If you’ve been diagnosed with smoldering multiple myeloma—especially if you’ve been told you’re high-risk—you’ve likely wondered: Should I treat my smoldering disease right now, or […]

November 6, 2025

How the Horizon One Trial Is Driving Innovation Just One Year In

Less than a year after enrolling its first patient, the Horizon One clinical trial already has important wins to celebrate: Not only is it pioneering important research for patients with relapsed and refractory multiple myeloma, but it’s enrolling a patient population that’s far more representative of the disease than other trials to date. The Horizon […]

November 4, 2025

Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities – Journal of Health Economics and Outcomes Research

October 16, 2025

Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans – Nature